Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19203342 | 0.80 | ALDH1A1 (0.39) | LMNAESR2ALDH1A1 | |
| SCHEMBL2658683 | 0.79 | LMNA (0.36) | LMNAESR2CES2 | |
| SCHEMBL2657608 | 0.79 | LMNA (0.36) | LMNAESR2CES2 | |
| SCHEMBL2658518 | 0.79 | LMNA (0.36) | LMNAESR2CES2 | |
| SCHEMBL8785666 | 0.76 | ALDH1A1 (0.36) | LMNACES2ALDH1A1TP53 | |
| SCHEMBL2947093 | 0.74 | MEN1 (0.43) | CES2ALDH1A1CYP3A4TDP1 | |
| SCHEMBL19440749 | 0.73 | PTGS2 (0.46) | LMNACES2 | |
| SCHEMBL3228269 | 0.73 | LMNA (0.32) | LMNA | |
| SCHEMBL14769174 | 0.72 | GPR119 (0.34) | ESR2 | |
| SCHEMBL15187972 | 0.70 | TRPV3 (0.41) | LMNAESR2TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-6821960-B2 | Glucagon antagonists/inverse agonists | NOYO NORDISK PHARMACEUTICALS, INC. | 2004-11-23 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| EP-1296942-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-20030027849-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3293/4885ESR2 191/4885CES2 2343/4885 |
| US-20030027849-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3715/4885ESR2 202/4885CES2 2616/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3293/4885ESR2 191/4885CES2 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.